Combination therapy for elevated low-density lipoprotein cholesterol: The key to coronary artery disease risk reduction

American Journal of Cardiology

Volumn 90, Issue 10 SUPPL. 2, 2002, Pages 8-20

  McKenney, Jim ^a  

^a National Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESEVELAM; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; DYSPEPSIA; EDUCATION PROGRAM; ENZYME DEFECT; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; MONOTHERAPY; MYOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037146191     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02967-3     Document Type: Article

References (37)

1. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:1995;69C-77C.
2. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828.
3. Iso H., Jacobs D.R. Jr, Wentworth D., Neaton J.D., Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 320:1989;904-910.
4. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
5. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
6. Thompson G.R. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease. Atherosclerosis. 131:1997;1-5.
7. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
8. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendörfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS . JAMA. 279:1998;1615-1622.
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
12. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
13. Collins R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomized placebo-controlled trial . Lancet. 360:2002;7-22.
14. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
15. Knatterud G.L., Rosenberg Y., Campeau L., Geller N.L., Hunninghake D.B., Forman S.A., Forrester J.S., Gobel F.L., Herd J.A., Hickey A., et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation. 102:2000;157-165.
16. Illingworth D.R. Management of hypercholesterolemia. Med Clin North Am. 84:2000;23-42.
17. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyöräla K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
18. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M., Eisenberg D., Shurzinske L., McCormick L.S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 341:1999;70-76.
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
20. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160:2000;459-467.
21. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith S.C., Alexander C.M., Londhe A., Lulla A., Simpson R.J. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
22. Simons L.S., Levis G., Simons J.J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. MJA. 164:1996;208-211.
23. Hunninghake D., Bakker-Arkema R.G., Wigand J.P., Drehobl M., Schrott H., Early J.L., Abdallah P., McBride S., Black D.M. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 47:1998;349-356.
24. Brown A.S., Bakker-Arkema R.G., Yellen L., Henley R.W. Jr, Guthrie R., Campbell C.F., Koren M., Woo W., McLain R., Black D.M. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 32:1998;665-672.
25. Ballantyne C.M., Andrews T., Hsia J.A., Kramer J.H., Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels . Am J Cardiol. 88:2001;265-269.
26. Andrews T.C., Ballantyne C.M., Hsia J.A., Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191.
27. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., Donovan J.M., Burke S.K., Davidson M.H. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 110:2001;352-360.
28. Hunninghake D., Insull W., Toth P., Davisdon D., Donovan J.M., Burke S.K. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 158:2001;407-416.
29. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
30. Wolfe M.L., Vartanian S.F., Ross J.L., Bansavich L.L., Mohler E.R., Meagher E., Friedrich C.A., Rader D.J. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 87:2001;476-478.
31. Vacek J.L., Dittmeier G., Chiarelli T., White J., Bell H.H. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 76:1995;182-184.
32. Kos Pharmaceuticals. Miami, FL. Advicor Package Insert, 2001.
33. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., Knopp R.H., Lipka L.J., Lebeaut A.P., Yang B., et al. Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia pooled analysis of two phase II studies . Clin Ther. 23:2001;1209-1230.
34. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L., LeBeaut A., Suresh R., Sun S., Veltri E. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl A):2002;226A. [poster session abstract].
35. Ballantyne C., Houri J., Notarbartolo A., Melani L., Lipka L., LeBeaut A., Suresh R., Sun S., Veltri E. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl A):2002;227A. [poster session abstract].
36. Bays H.E., Weiss S., Gagne C., Mata P., Gumbiner B., Melmo M., Quinto K., Cho M. Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral contributions. J Am Coll Cardiol. 39:(suppl A):2002;245A.
37. Gagne C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 105:2002;2469-2475.